PubMed Health⌕ Search

Biomedical subjects

E S Vitetta

Publications and source records attributed to E S Vitetta.

At least 145 records · Page 8Linked to original sources
PubMed1988

Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells.

The regulation of the subclass of immunoglobulin secreted by B cells has been studied in vitro in polyclonal systems using mitogens, such as lipopolysaccharide (LPS), to bypass the requirement for cognate interaction between antigen-specific T and B cells. In these systems, interleukin-(IL)-4 induces the secretion of IgG1 (ref. 1) and IgE (ref. 2); IL-5 enhances the secretion of IgA, and interferon-gamma (IFN-gamma) enhances the secretion of IgG2a (ref. 5). Clones of murine TH cells can be divided into two subsets, TH1 and TH2 (ref. 6). Both subsets synthesize IL-3 and granulocyte-monocyte colony-stimulating factor (GM-CSF), but only TH1 clones produce IL-2, IFN-gamma, and lymphotoxin (LT) and TH2 clones produce IL-4 and IL-5 (ref. 7). We have examined the role of clones of antigen-specific TH1 and TH2 cells in the regulation of the subclasses of IgG antibody secreted by antigen-specific B cells. Our results show that both types of TH cells induce the secretion of IgM and IgG3, whereas clones of TH1 and TH2 cells specifically induce antigen-specific B cells to secrete IgG2a and IgG1, respectively. We also demonstrate that regulation of commitment to the secretion of a particular IgG isotype occurs in two distinct stages: cognate interaction between T and B cells and interaction between T-cell-derived lymphokines and B cells.

Animals↗
PubMed1988

Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization.

The blood clearance and tissue distribution of immunotoxins composed of either intact or Fab' fragments of tumor-reactive, monoclonal rat antimurine immunoglobulin D (anti-delta) or nonreactive, normal rat immunoglobulin G and ricin A chain (native or chemically deglycosylated) were determined in BCL1 tumor-bearing mice. In the presence of accessible target cells, neither the valency of the antibody nor deglycosylation of the A chain affect the initial rate of clearance (alpha phase) of immunotoxins from the blood; however, both factors affect the levels of tumor-specific and nonspecific localization of the immunotoxins. Thus, the use of immunotoxins with deglycosylated A chain greatly reduced the levels of nonspecific uptake by the liver and concomitantly increased tumor-specific localization. Immunotoxins prepared with Fab' fragments of anti-delta antibody and deglycosylated A chain were twice as effective at localizing to splenic tumor than immunotoxins prepared with intact immunoglobulin G and deglycosylated A chain. Approximately 90% of tumor-specific localization of anti-delta immunotoxins occurred within 1 h after injection and less than 5% of the immunotoxin remained in the circulation 4 h after injection. In addition, the antigen-binding capacity of the remaining circulating immunotoxins decreased in a linear manner over the first 10 h to approximately 20% of the initial binding activity. Thus, by 10 h after injection, only 2-3% of injected immunotoxin remained in the circulation and this material expressed little antigen reactivity. Analysis of the in vivo stability of circulating 125I-labeled immunotoxins in tumor-bearing mice demonstrated that Fab' immunotoxins are more stable than IgG immunotoxins prepared with N-succinimidyl-3-(2-pyridylthio)propionate. In BCL1-bearing mice, significant splitting of the anti-delta immunotoxins did not occur until tumor localization was virtually complete.

Animals↗
PubMed1988

In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.

The in vivo therapeutic effects of Fab' and IgG anti-delta (anti-IgD)-ricin A chain immunotoxins were compared in mice bearing the surface IgD-positive BCL1 leukemia. The immunotoxins were prepared with either native or deglycosylated ricin A chain. Immunotoxin therapy was assessed both by the number of cells bearing the BCL1 immunoglobulin idiotype which remained in the spleen 24-48 h after injection with immunotoxin and by adoptive transfer of these spleen cells into normal mice. Immunotoxins prepared with either Fab'-anti-delta or IgG-anti-delta and native A chain induced a dose-dependent reduction in the number of idiotype-positive BCL1 cells present in the spleens of the tumor-bearing mice. The maximal therapeutic response was achieved with 250 micrograms of immunotoxin (containing 80-100 micrograms A chain) per mouse for both immunotoxins, resulting in tumor reduction of approximately 90%. This represents an elimination of 3-4 X 10(8) tumor cells. Reduction in the number of tumor cells was not observed with control reagents including antibody alone, antibody mixed with A chain, or an immunotoxin of irrelevant specificity. A Fab' immunotoxin prepared with deglycosylated ricin A chain was approximately 5-fold more effective as an antitumor reagent than the same immunotoxin prepared with native A chain; thus, optimal therapy was achieved after injection of 50 micrograms of immunotoxin (containing 15-20 micrograms A chain). Since the immunotoxins prepared with deglycosylated A chain were only 2-3-fold more toxic to the mice than those prepared with native A chain, the former resulted in a 2-3-fold increase in the therapeutic index.

Animals↗
PubMed1988

An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins.

In this report, we describe an assay for screening monoclonal antibodies for their cytotoxic potential as ricin A chain-containing immunotoxins. The assay involves treating cells with dilutions of the test antibody followed by a Fab fragment of a secondary antibody coupled to ricin A chain ("indirect assay"). The cytotoxicity of the indirect assay is compared to that of the direct assay where the monoclonal antibody is coupled to ricin A chain. Indirect and direct assays were carried out using 14 antibodies and a panel of 8 human and mouse cell types. The two assays showed virtually 100% correlation. The indirect assay, therefore, predicts the potency of a given monoclonal antibody to make an effective immunotoxin and should be useful in screening monoclonal antibodies for use as immunotoxins.

Antibodies, Monoclonal↗
PubMed1988

A single antigen-specific B cell can conjugate to either a type 1 or a type 2 helper T cell.

Keyhole-limpet-hemocyanin-specific I-Ad-restricted T helper cells type 1 (TH1 cells) and type 2 (TH2 cells) were studied for their ability to physically conjugate to trinitrophenyl-specific antigen-binding B cells (TNP-ABCs). The same TNP-ABCs (which had already processed TNP-keyhole limpet hemocyanin) formed conjugates with one or the other T helper (TH) cell type, and conjugation was antigen-specific and major histocompatibility complex-restricted. The conjugation of a fixed number of one type of TH cell to the TNP-ABCs was inhibited by co-incubation with increasing numbers of cells of the other TH cell type. Thus, the vast majority of TNP-ABCs can conjugate to either type of TH cell. A similar pattern of inhibition of the conjugation of one TH cell type to the TNP-ABCs was seen when cells were co-incubated with increasing numbers of cells from an alloreactive T-cell clone. In all cases, conjugates contained only one T cell bound to one B cell, suggesting that interaction of an antigen-presenting B cell with one TH cell prevents the simultaneous binding of another TH cell.

Animals↗
PubMed1988

Epitopes on CD45R [T200] molecules define differentiation antigens on murine B and T lymphocytes.

In the course of isolating hybridomas from rats that had been immunized with anti-Ig activated murine B lymphoblasts, we have identified three new mAb reactive with the T200 or leukocyte common antigen family (CD45). One, MB4B4, reacts with T200 on all leukocytes, and immunoprecipitates all the molecules that are recognized by an existing mAb to this family. Two others, MB23G2 and MB15C11, react with a subset of T200 molecules that has a unique tissue and cellular distribution. By FACS analysis and by immunocytochemical labeling of tissue sections, MB23G2/15C11 bind to most, if not all, small B and T lymphocytes, but react weakly with macrophages and dendritic cells. Expression of the MB23G2/15C11 T200 epitope exhibits four distinct features on lymphocytes: 1) activation of CD4+ cells in the mixed leukocyte reaction results in a decreased expression of MB23G2/15C11, on a subset of 30-60% of the T-cell blasts; 2) of 16 T-helper clones examined, clones of the TH2 phenotype express moderate to high levels of MB23G2/15C11 (2.5-19-fold increase in median fluorescence over control) while the TH1 clones express low to moderate levels (1.2-6.4-fold increase in median fluorescence over control) of the antigen recognized by these mAb; 3) The MB23G2/15C11 mAb do not react with germinal center cells in tissue sections of spleen, lymph node, and Peyer's patches; 4) MB23G2/15C11 reacts primarily with a subset of large thymocytes localized to the medulla. Therefore, MB23G2/15C11 define a subset-restricted form of T200 (CD45R) on murine lymphocytes. The tissue distribution of this T200 associated epitope is distinct from previously defined CD45 antigens and suggests a role during several pathways of lymphocyte development.

Animals↗
PubMed1988

Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease.

Data from human clinical trials and animal experiments have suggested that T lymphocytes in donor marrow help to facilitate engraftment after allogeneic bone marrow transplantation, possibly through a suppressive effect on the immunity of the recipient. In previous studies marrows from HLA-identical donors were treated ex vivo with a mixture of eight monoclonal antibodies together with rabbit complement to achieve a 3-log depletion of T cells and CD3-negative lymphoid cells. Transplantation of this marrow was associated with a 27% actuarial risk of graft failure in leukemic recipients conditioned with cyclophosphamide (120 mg/kg) and 15.75 Gy fractionated total body irradiation. In the present study, we employed an anti-CD3 ricin A-chain-containing immunotoxin (64.1-A) together with 20 mM NH4Cl to achieve a selective 3-log depletion of CD3-positive cells. The patient entry criteria and pretransplant conditioning regimen were identical to those used in previous studies. Despite the differences in marrow treatment, the clinical outcome of the present study was similar to that obtained previously. Graft-versus-host disease (GVHD) was largely prevented without the need for post-transplant immunosuppression, but two of the eight patients developed graft failure. These results indicate that CD3-negative cells have little or no ability to initiate GVHD. To the extent that graft failure in this study was not caused by stem cell damage or loss of CD3-negative cells during ex vivo processing of the marrow, it appears that the lymphoid cells required for facilitating allogeneic engraftment under these conditions are CD3-positive.

Adult↗
PubMed1988

The development of immunotoxins for the therapy of cancer, AIDS, and immune dysfunctions.

Immunotoxins (ITs) consist of cell-reactive ligands coupled to toxins or their toxic subunits. The ligands are usually antibodies, hormones, or growth factors and the toxins are of bacterial or plant origin. In the case of the plant toxin, ricin, its structure consists of a ribosome-inactivating A chain of 32 Kd linked by a disulfide bond to a galactose-specific lectin (B chain) of approximately 30 Kd. The A and B chains of ricin can be separated following reduction and the A chain can then be purified and chemically linked to different ligands to generate a cell-reactive conjugate. Studies using A chain-containing ITs to specifically delete tumor cells, or regulatory cells of the immune system began a decade ago. Initial in vitro experiments were successful and led to further experiments in vivo. However, in vivo studies carried out over the past five years in both animals and humans have demonstrated that the efficacy of ITs or conjugates in vivo is often poor due to problems involving instability of the conjugate, inferior potency, inaccessibility of tumor cells, nonspecific binding to cells other than the target cells, and the survival of antigen-negative mutants. In addition, immune responses against both the ligand and the A chain are usually elicited, precluding repeated therapy. During the past several years, there have been attempts to solve these problems and thereby develop more effective ITs. By analogy with conventional chemotherapeutic agents, it could be predicted that immunotoxins will require many years of study to optimize their construction and therapeutic regimens.(ABSTRACT TRUNCATED AT 250 WORDS)

Acquired Immunodeficiency Syndrome↗
PubMed1987

Redesigning nature's poisons to create anti-tumor reagents.

Immunotoxins are conjugates of cell-reactive antibodies and toxins or their subunits. In this report, the chemistry, biology, pharmacokinetics, and anti-tumor effects of first generation immunotoxins; the preparation of improved second generation immunotoxins that display greater anti-tumor efficacy; and the role of genetic engineering in creating third-generation immunotoxins are discussed.

Animals↗
PubMed1987

Interleukin 4 enhances the ability of antigen-specific B cells to form conjugates with T cells.

T cell-B cell conjugates are formed when trinitrophenyl-specific B cells are exposed to trinitrophenyl-ovalbumin and ovalbumin-specific T hybridoma cells. The proportion of conjugates was increased two- to threefold when antigen-pulsed trinitrophenyl-specific B cells, but not T cells, were pre-exposed to interleukin 4. Antigen-specific B cells pretreated with antigen and interleukin 4 and cultured in the presence of specific T helper cells also produced a larger proportion of antibody-secreting cells as compared to cells pretreated with antigen alone. The interleukin 4-induced enhancement of T/B conjugate formation occurred over a wide range of antigen concentrations, was dependent on the concentration of interleukin 4, and was inhibited by the monoclonal anti-interleukin 4 antibody, 11B11. The importance of Ia antigens in the enhancement of conjugate formation and generation of antibody-secreting cells is suggested by a) the fact that the interleukin 4-mediated increase in the density of Ia antigens on the antigen-specific B cells correlated with their enhanced ability to form T/B conjugates, b) the kinetics of the interleukin 4-mediated increase in conjugate formation and surface Ia expression were similar, c) 10- to 20-fold higher concentrations of anti-I-A antibody were required to inhibit T/B conjugate formation by 50% with interleukin 4-treated antigen-specific B cells compared with untreated antigen-specific B cells, and d) interferon-gamma, which inhibits the interleukin 4-mediated increase in Ia antigens, inhibited the interleukin 4-induced enhancement of T/B conjugate formation. These results indicate that the interleukin 4-induced increase in the expression of Ia antigens on B cells plays an important role in the enhancement of T/B cell interactions and the subsequent differentiation of antigen-specific B cells into antibody-secreting cells.

Animals↗
PubMed1987

Inhibition of the helper function of murine T cells with Fab'-anti-L3T4 ricin A chain immunotoxin.

The ability of Fab'-anti-L3T4 A chain-containing immunotoxins to inhibit the helper function of keyhole limpet hemocyanin-specific T helper lymphocytes was evaluated. Keyhole limpet hemocyanin-specific T helper cells were prepared from the lymph nodes of primed mice and were enriched for T cells. Enriched populations of trinitrophenyl-specific B cells were prepared from spleens of normal mice. In the presence of antigen, the keyhole limpet hemocyanin-specific T helper cells were able to induce proliferation and differentiation of the trinitrophenyl-specific B cells. However, when the T helper cells were first treated with an immunotoxin composed of Fab' fragments of anti-L3T4 antibody coupled to ricin A chain (Fab'-anti-L3T4-A), they failed to induce proliferation and differentiation of the antigen-specific B cells. The concentrations of Fab'-anti-L3T4-A required to inhibit T cell help for the proliferation and differentiation of trinitrophenyl-specific B cells by 50% were 1 X 10(-9)M and 4 X 10(-10) M, respectively. Fab'-anti-L3T4 antibody alone did not inhibit T cell-induced B cell proliferation and differentiation by 50% at greater than 100-fold higher concentrations.

Animals↗
PubMed1987

Antigen-induced changes in phospholipid metabolism in antigen-binding B lymphocytes.

Previous studies have demonstrated a marked change in the metabolism of phospholipids (PL) after activation of resting B lymphocytes with anti-immunoglobulin (anti-Ig). In this study we examined PL metabolism in highly purified trinitrophenyl (TNP)-binding B cells after their activation with various forms of TNP-carrier protein. Such cells show similar changes in PL metabolism when stimulated with either antigen or anti-Ig, i.e., increased incorporation of 32PO4 into phosphatidic acid and phosphatidyl inositol (PI) but not phosphatidyl choline, phosphatidyl ethanolamine, or phosphatidyl serine. We have demonstrated that these responses to antigen are TNP-specific and dose-related between 1 and 50 micrograms/ml, producing up to a 2.5-fold stimulation of 32PO4 incorporation into PI. The PL response is also directly related to the density of TNP on the carrier and can be augmented by additional cross-linking of the carrier protein. These data suggest that cross-linking of surface Ig by antigen induces a change in PL metabolism as an early event in B cell activation.

Animals↗
PubMed1987

Antigen-specific memory and virgin B cells differ in their requirements for conjugation to T cells.

The physical interaction between carrier-specific T hybridoma cells and long-term primed, TNP-specific memory B cells (TNP-MABC) exposed to TNP-OVA was compared to that of unprimed, TNP-specific virgin B cells (TNP-ABC). The direct conjugation of the T and B cells was visualized at the light microscopic level and the number of T/B conjugates was quantified directly. The results demonstrate that the TNP-MABC, as compared to TNP-ABC, formed T/B conjugates after a shorter exposure time to antigen and at a 10-fold lower concentration of antigen. Conjugate formation was inhibited almost completely by treating the TNP-MABC with concentrations of chloroquine that only partially inhibited the ability of the TNP-ABC to form conjugates. Exposure of the T hybridoma cells or the TNP-ABC to monoclonal antibodies directed against cell surface antigens prior to conjugation indicated that L3T4, Thy-1.2, and LFA-1 antigens on the T cells and LFA-1 and I-A antigens on the TNP-ABC are involved in conjugate formation. However, in contrast to the TNP-ABC where treatment of the B cells with anti-LFA-1 blocked T/B conjugate formation, pretreatment of the TNP-MABC with anti-LFA-1 had no effect.

Animals↗
PubMed1987

The effects of cytokines and adherent cells on the interleukin 4-mediated induction of Ia antigens on resting B cells.

In this report we have extended our previous studies on interleukin 4 (IL-4) [previously termed B-cell stimulatory factor-1 (BSF-1)]. Our results demonstrate that 8 hr of exposure to IL-4 is sufficient to induce maximal expression of Ia antigens. This increase in expression of Ia antigens on resting B cells is due to the direct action of IL-4 on the B cells since adding or removing adherent cells or utilizing low density cultures of B cells at 50-100/culture had no effect on the IL-4-mediated increase in Ia. Monoclonal anti-IL-4 antibody completely abrogated the Ia-inducing activity of IL-4. A variety of other purified lymphokines including interleukin 2 (IL-2), interleukin 1 (IL-1), and a source of either B-cell differentiation factor for IgM (BCDF mu), or B-cell growth factor II (BCGF II), did not alter the expression of Ia antigens on resting B cells. However, interferon-gamma can partially inhibit the IL-4-mediated induction of Ia.

Animals↗
PubMed1987

Cloning and expression of recombinant, functional ricin B chain.

The cDNA encoding the B chain of the plant toxin ricin has been cloned and expressed in monkey kidney COS-M6 cells. The recombinant B chain was detected by labeling the transfected cells with [35S]methionine and [35S]-cysteine and demonstrating the secretion of a protein with a Mr of 30,000-32,000 that was not present in the medium of mock-transfected COS-M6 cells. This protein was specifically immunoprecipitated by an anti-ricin or anti-B-chain antibody and the amount of recombinant B chain secreted by the COS-M6 cells was determined by a radioimmunoassay. Virtually all of the recombinant B chain formed active ricin when mixed with native A chain; it could also bind to the galactose-containing glycoprotein asialofetuin as effectively as native B chain. These results indicate that the vast majority of recombinant B chains secreted into the medium of the COS-M6 cells retain biological function.

Animals↗
PubMed1987

Activation of murine B cells with Salmonella typhimurium mitogen (STM), lipopolysaccharide (LPS), and dextran sulfate (DxS). I. Cell-cycle analysis and induction of cytoplasmic immunoglobulin.

There have been two recent reports concerning a B cell-specific mitogen that induces proliferation, but not differentiation of rat and human B cells. This mitogen, which is derived from Salmonella typhimurium (STM), appears to be providing the signals required for anti-immunoglobulin-treated (anti-Ig) B cells to enter cycle and divide, but may not be inducing responsiveness to B cell differentiation factors (BCDF). In this report, we have compared STM to the other known murine B cell polyclonal activators: lipopolysaccharide (LPS), dextran sulfate (DxS), and the combination of LPS/DxS. STM was the most potent stimulus of B cell proliferation as determined by uptake of 3H-thymidine, viable cell numbers and cell cycle analysis utilizing acridine orange (AO). STM did not induce significant proliferation of murine T lymphocytes. In addition, the proliferative effect of STM on B cells shows minimal, if any, macrophage dependence. However, in contrast to its effect on human and rat B cells, STM induces differentiation of murine B cells. The levels of cytoplasmic Ig induced by STM are equivalent or greater to those induced by LPS/DxS. Thus, in the murine system, STM will be useful as a polyclonal activator which induces proliferation and differentiation of the vast majority of the B cell population without stringent accessory cell requirements.

Animals↗